UM

Browse/Search Results:  1-8 of 8 Help

Selected(0)Clear Items/Page:    Sort:
Schisantherin a attenuates neuroinflammation in activated microglia: Role of Nrf2 activation through ERK phosphorylation Journal article
Cellular Physiology and Biochemistry, 2018,Volume: 47,Issue: 5,Page: 1769-1784
Authors:  Li C.;  Chen T.;  Zhou H.;  Zhang C.;  Feng Y.;  Tang F.;  Hoi M.P.-M.;  He C.;  Zheng Y.;  Lee S.M.-Y.
Favorite  |  View/Download:2/0  |  Submit date:2018/11/06
Microglia  Neuroinflammation  NF-κB  Nrf2  Schisantherin A  
Schisantherin A Attenuates Neuroinflammation in Activated Microglia: Role of Nrf2 Activation Through ERK Phosphorylation Journal article
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018,Volume: 47,Issue: 5,Page: 1769-1784
Authors:  Li, Chuwen;  Chen, Tongkai;  Zhou, Hefeng;  Zhang, Chao;  Feng, Yu;  Tang, Fan;  Hoi, Maggie Pui-Man;  He, Chengwei;  Zheng, Ying;  Lee, Simon Ming-Yuen
Favorite  |  View/Download:13/0  |  Submit date:2018/10/30
Schisantherin a  Neuroinflammation  Microglia  Nrf2  Nf-kappa b  
Small-Sized mPEG-PLGA Nanoparticles of Schisantherin A with Sustained Release for Enhanced Brain Uptake and Anti-Parkinsonian Activity Journal article
ACS Applied Materials and Interfaces, 2017,Volume: 9,Issue: 11,Page: 9516-9527
Authors:  Chen T.;  Li C.;  Li Y.;  Yi X.;  Wang R.;  Lee S.M.-Y.;  Zheng Y.
Favorite  |  View/Download:1/0  |  Submit date:2018/12/28
brain delivery  cellular uptake  fluorescence resonance energy transfer (FRET)  mPEG−PLGA nanoparticles  oral bioavailability  Schisantherin A  
Small-Sized mPEG PLGA Nanoparticles of Schisantherin A with Sustained Release for Enhanced Brain Uptake and Anti-Parkinsonian Activity Journal article
ACS APPLIED MATERIALS & INTERFACES, 2017,Volume: 9,Issue: 11,Page: 9516-9527
Authors:  Chen, Tongkai;  Li, Chuwen;  Li, Ye;  Yi, Xiang;  Wang, Ruibing;  Lee, Simon Ming-Yuen;  Zheng, Ying
Favorite  |  View/Download:11/0  |  Submit date:2018/10/30
Brain Delivery  Cellular Uptake  Fluorescence Resonance Energy Transfer (Fret)  Mpeg-plga Nanoparticles  Oral Bioavailability  Schisantherin a  
Oral delivery of a nanocrystal formulation of schisantherin a with improved bioavailability and brain delivery for the treatment of Parkinson's disease Journal article
Molecular Pharmaceutics, 2016,Volume: 13,Issue: 11,Page: 3864-3875
Authors:  Chen T.;  Li C.;  Li Y.;  Yi X.;  Lee S.M.-Y.;  Zheng Y.
Favorite  |  View/Download:4/0  |  Submit date:2018/11/06
Brain Delivery  Dissolution  Nanocrystals  Oral Bioavailability  Parkinson's Disease (Pd)  
Schisantherin A protects against 6-OHDA-induced dopaminergic neuron damage in zebrafish and cytotoxicity in SH-SY5Y cells through the ROS/NO and AKT/GSK3β pathways Journal article
Journal of Ethnopharmacology, 2015,Volume: 170,Page: 8-15
Authors:  Zhang L.Q.;  Sa F.;  Chong C.M.;  Wang Y.;  Zhou Z.Y.;  Chang R.C.C.;  Chan S.W.;  Hoi P.M.;  Yuen Lee S.M.
Favorite  |  View/Download:2/0  |  Submit date:2018/11/06
6-hydroxydopamine(6-OHDA)  Oxidativestress  Parkinson'sdisease  Schisantherin A  
Discovery of novel anti-parkinsonian effect of schisantherin A in in vitro and in vivo Journal article
Neuroscience Letters, 2015,Volume: 593,Page: 7-12
Authors:  Sa F.;  Zhang L.Q.;  Chong C.M.;  Guo B.J.;  Li S.;  Zhang Z.J.;  Zheng Y.;  Hoi P.M.;  Lee S.M.Y.
Favorite  |  View/Download:6/0  |  Submit date:2018/11/06
Bcl-2  Dibenzocyclooctadiene lignans  Neuroprotection  Schisantherin a  
Pharmacokinetic study and optimal formulation of new anti-parkinson natural compound schisantherin A Journal article
Parkinson's Disease, 2015,Volume: 2015
Authors:  Sa F.;  Guo B.J.;  Li S.;  Zhang Z.J.;  Chan H.M.;  Zheng Y.;  Lee S.M.Y.
Favorite  |  View/Download:3/0  |  Submit date:2018/11/06